탈모증 시장 규모, 점유율, 동향 분석 보고서 : 질환 유형별, 치료별, 성별, 판매 채널별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Alopecia Market Growth & Trends:

The global alopecia market size is expected to reach USD 16.02 billion by 2030, registering a CAGR of 8.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The approval of JAK inhibitors and tyrosine kinase inhibitors along with the rising target disease prevalence is expected to drive market growth.

The prevalence of alopecia areata (AA) and alopecia to talis is increasing globally. It is one of the most commonly encountered problems in clinics in the U.S. As per a research article published in March 2023, in the U.S. and UK, AA accounted for 0.6% to 2% of the new cases encountered in dermatology clinics. In hospital-based studies performed worldwide the incidence of AA is estimated to range between 0.57% to 3.8%.

The approval of new targeted pharmaceutical treatments is a key factor driving the alopecia market growth. For instance, in June 2022, the U.S. FDA approved Lilly's Olumiant oral tablets for the treatment of severe alopecia in adult patients and is the first systemic treatment approved. Another key drug that is anticipated to be approved in 2023 is Pfizer's Ritlecitinib. It is a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinases.

Another key factor driving the industry's growth is the increasing awareness regarding alopecia and thereby increasing treatment rates worldwide. The increase in the level of consciousness regarding physical appearance is one of the major reasons for the rising number of people seeking treatment. Additionally, rising investments in R&D and funding are also fueling market growth.

The limited availability of targeted drugs that treat the underlying condition is one key challenge for the market. While new products with targeted mechanisms of action are being approved the high cost of these drugs in comparison to the already approved products is one of the major hindrances in their widespread adoption.

Alopecia Market Report Highlights:

• The alopecia universalis segment is expected to witness the fastest growth from 2025 to 2030, owing to the impending approval of pipeline products, such as Pfizer's Ritlecitinib which is in the pre-registration phase, and Bioniz Therapeutics's BNZ-1 which is in phase 2 clinical trials
• North America dominated the market in 2024, mainly due to the high consumer awareness, technological advancements, high target disease population, and high healthcare spending
• Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be majorly attributed to the rising target disease population and rising treatment rate for the disease.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease Type
  • 1.2.2. Treatment
  • 1.2.3. Gender
  • 1.2.4. Sales Channel
  • 1.2.5. End Use
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease Type
  • 2.2.2. Treatment
  • 2.2.3. Gender
  • 2.2.4. Sales Channel
  • 2.2.5. End Use
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Alopecia Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing global prevalence of alopecia
    • 3.2.1.2. Increasing global healthcare expenditure
    • 3.2.1.3. Increasing prevalence of chronic diseases
      • 3.2.1.3.1. PCOS
      • 3.2.1.3.2. Cancer
      • 3.2.1.3.3. Rheumatoid Arthritis
    • 3.2.1.4. Technological advancements in alopecia treatment
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of reimbursement policies for alopecia treatment
    • 3.2.2.2. Increasing adoption of substitutes
• 3.3. Alopecia Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Patent Expiry Analysis
• 3.5. Pipeline Analysis
  • 3.5.1. Phase 1
  • 3.5.2. Phase 2
  • 3.5.3. Phase 3

Chapter 4. Alopecia Market: Disease Type Estimates & Trend Analysis

• 4.1. Disease Type Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Alopecia Market by Disease Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Alopecia Areata
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Male
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Female
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Cicatricial Alopecia
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Male
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Female
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Traction Alopecia
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.2. Male
      • 4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.3. Female
      • 4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Alopecia Totalis
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4.2. Male
      • 4.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4.3. Female
      • 4.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Alopecia Universalis
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.2. Male
      • 4.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.3. Female
      • 4.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Androgenetic Alopecia
    • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6.2. Male
      • 4.4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6.3. Female
      • 4.4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.7. Others
    • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7.2. Male
      • 4.4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7.3. Female
      • 4.4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Alopecia Market: Treatment Estimates & Trend Analysis

• 5.1. Treatment Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Alopecia Market by Treatment Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Pharmaceuticals
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2. Topical
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.2. OTC
        • 5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.2.2.2. Minoxidil
          • 5.4.1.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.2.2.3. Others
          • 5.4.1.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.3. Prescription
        • 5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.2.3.2. Betamethasone Dipropionate
          • 5.4.1.2.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.2.3.3. Fluocinolone Acetonide
          • 5.4.1.2.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.2.3.4. Finasteride
          • 5.4.1.2.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.2.3.5. Minoxidil
          • 5.4.1.2.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3. Oral
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.2. OTC
        • 5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.3. Prescription
        • 5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.3.3.2. Minoxidil
          • 5.4.1.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.3.3.3. Finasteride
          • 5.4.1.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.3.3.4. Corticosteroids
          • 5.4.1.3.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.3.3.5. Others (JAK inhibitors and others)
          • 5.4.1.3.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.4. PRP
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Devices
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2. Laser Cap
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.2. Laser Comb
      • 5.4.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.4. Laser Helmet
      • 5.4.2.2.5. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Alopecia Market: Gender Estimates & Trend Analysis

• 6.1. Gender Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Alopecia Market by Gender Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Male
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Female
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Alopecia Market: Sales Channel Estimates & Trend Analysis

• 7.1. Sales Channel Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Alopecia Market by Gender Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Prescription
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. OTC
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Alopecia Market: End Use Estimates & Trend Analysis

• 8.1. End Use Market Share, 2024 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Alopecia Market by End Use Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Homecare Settings
    • 8.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Dermatology Clinics
    • 8.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Alopecia Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. U.S.
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. Canada
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. Mexico
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Europe
  • 9.6.1. UK
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. Germany
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. France
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/ reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. Italy
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/ reimbursement structure
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Spain
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/ reimbursement structure
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Norway
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/ reimbursement structure
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.7. Sweden
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/ reimbursement structure
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.8. Denmark
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/ reimbursement structure
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Japan
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. China
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. India
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. Australia
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.5. South Korea
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/ reimbursement structure
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.6. Thailand
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/ reimbursement structure
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Brazil
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework/ reimbursement structure
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.2. Argentina
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/ reimbursement structure
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. South Africa
    • 9.9.1.1. Key country dynamics
    • 9.9.1.2. Regulatory framework/ reimbursement structure
    • 9.9.1.3. Competitive scenario
    • 9.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.2. Saudi Arabia
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/ reimbursement structure
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.3. UAE
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/ reimbursement structure
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.4. Kuwait
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/ reimbursement structure
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. Key company market share analysis, 2024
  • 10.3.2. Janssen Global Services Inc.
    • 10.3.2.1. Company overview
    • 10.3.2.2. Financial performance
    • 10.3.2.3. Product benchmarking
    • 10.3.2.4. Strategic initiatives
  • 10.3.3. Cipla
    • 10.3.3.1. Company overview
    • 10.3.3.2. Financial performance
    • 10.3.3.3. Product benchmarking
    • 10.3.3.4. Strategic initiatives
  • 10.3.4. Merck & Co., Inc.
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. GSK plc
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Sun Pharmaceuticals Industries Ltd
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Dr. Reddy's Laboratories Ltd
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Aurobindo Pharma
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Viatris Inc.
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Pfizer, Inc.
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Eli Lilly and Company
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Lexington Intl., LLC (Devices)
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Product benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Freedom Laser Therapy (iRestore ID-520 helmet)
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Product benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Curallux, LLC.
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Product benchmarking
    • 10.3.14.4. Strategic initiatives
  • 10.3.15. Apira Science Inc. (iGROW Laser)
    • 10.3.15.1. Company overview
    • 10.3.15.2. Financial performance
    • 10.3.15.3. Product benchmarking
    • 10.3.15.4. Strategic initiatives
  • 10.3.16. Revian Inc.
    • 10.3.16.1. Company overview
    • 10.3.16.2. Financial performance
    • 10.3.16.3. Product benchmarking
    • 10.3.16.4. Strategic initiatives
  • 10.3.17. Theradome
    • 10.3.17.1. Company overview
    • 10.3.17.2. Financial performance
    • 10.3.17.3. Product benchmarking
    • 10.3.17.4. Strategic initiatives
  • 10.3.18. Lutronic
    • 10.3.18.1. Company overview
    • 10.3.18.2. Financial performance
    • 10.3.18.3. Product benchmarking
    • 10.3.18.4. Strategic initiatives